Summary of the Conference Call for 康龙化成 (Kanglong Chemical) Company Overview - 康龙化成 is a leading player in the pharmaceutical and biotechnology services industry, focusing on laboratory services, small molecule CDMO (Contract Development and Manufacturing Organization), and clinical services. Key Financial Highlights - In 2025, the company achieved revenue of 140.95 billion CNY, a year-on-year increase of 14.8% [3] - Adjusted net profit was 18.16 billion CNY, up 13% year-on-year, while net profit attributable to shareholders decreased by 7.2% due to significant investment gains in 2024 [3] - Revenue from the top 20 global pharmaceutical companies grew by 29.4%, accounting for 20% of total revenue [3] - New orders increased by over 14% year-on-year, with more than 950 new clients contributing approximately 4% to revenue [3] Business Segment Performance Laboratory Services - Revenue reached 81.59 billion CNY, a 15.8% increase year-on-year, with a gross margin of 44.7% [5] - The segment participated in 887 global new drug discovery projects, showing an increase from 2024 [5] - The growth was driven by the integration of AI and automation technologies, enhancing research efficiency [5] Small Molecule CDMO - Revenue was 34.83 billion CNY, up 16.5% year-on-year, with a gross margin of 33.8% [6] - The segment saw significant order growth, particularly in the second half of the year, with Q4 revenue reaching 11.9 billion CNY [6] - The number of late-stage projects increased significantly, with 47 Phase III projects and 34 commercial projects [7] Clinical CRO Services - The clinical business saw a slight increase in new orders, with overseas business achieving double-digit growth, accounting for over 35% of total revenue [14] - Domestic CRO and SMO services showed modest growth, with signs of price recovery in the market [14] Strategic Developments - The company made significant strides in commercialization, with API production facilities in Ningbo and Shaoxing passing FDA inspections, leading to the approval of its first commercial API for the U.S. market [3][12] - A major commercial agreement was signed with a multinational corporation for the production of oral small molecule GLP-1 formulations [3] - The ADC (Antibody-Drug Conjugate) production facility has been launched, and a new large-scale peptide API solid-phase synthesis facility is expected to be completed by 2026 [6][11] Market Outlook - For 2026, the company projects revenue growth of 12% to 18%, with a strong order pipeline and expected acceleration in CDMO revenue growth [8][15] - The company anticipates that the CDMO segment will continue to outpace overall company growth, with further improvements in revenue share and profitability [8][10] - The company is well-positioned to leverage its integrated service platform and technological advancements to attract more clients and enhance service delivery [15] Risks and Challenges - Potential impacts from currency fluctuations, particularly the appreciation of the RMB against the USD, are acknowledged, but the company expects revenue growth to offset these effects [8][15] - The clinical business may still be influenced by low-priced orders signed in previous years, affecting revenue in 2026 [14] Conclusion - 康龙化成 demonstrated robust growth in 2025, with strong performances across its core business segments. The company is optimistic about its future prospects, driven by a solid order backlog and strategic partnerships, despite facing some external economic challenges [16][17]

Investment Rating - The investment rating for the company is "Accumulate" [2][7] Core Views - The company reported a revenue of 6.67 billion yuan for 2025, representing a year-on-year growth of 14.91%, with a net profit attributable to shareholders of 1.13 billion yuan, up 19.35% year-on-year [2][3] - The company has a strong order backlog, with significant growth in emerging businesses, particularly in the CDMO (Contract Development and Manufacturing Organization) sector [3][4] - The company expects revenue growth to accelerate in 2026, with guidance indicating a revenue increase of 19%-22% [6] Financial Performance - In 2025, the company achieved a gross margin of 42.0%, a slight decrease of 0.4 percentage points year-on-year, primarily due to the increased proportion of lower-margin emerging businesses [4] - The company’s R&D investment for 2025 was 593 million yuan, reflecting a commitment to exploring and applying cutting-edge technologies [4] - The net profit for 2026 is projected to be 1.42 billion yuan, with an EPS of 3.93 yuan per share, corresponding to a PE ratio of 28.20 times [7][10] Business Segments - The small molecule CDMO segment generated revenue of 4.735 billion yuan in 2025, with a year-on-year growth of 3.59% [3] - Emerging businesses saw a revenue increase of 57.30% in 2025, with international revenue growing over 240% [3] - The company has a robust pipeline with 294 ongoing clinical research projects, including 122 in Phase II and beyond [3][4]

Core Insights - The company reported a revenue of $257 million for the year ending December 31, 2025, representing a year-on-year growth of 0.7% [2] - The profit attributable to shareholders was $6.793 million, showing a significant increase of 758.8% compared to the previous year [2] - Basic earnings per share were reported at $0.0034 [2] Revenue Breakdown - Revenue from North America and Europe experienced a slight decline, primarily due to a decrease in earnings from drug discovery services [2] - The decline in North American and European revenue was attributed to pharmaceutical and biotechnology companies optimizing their R&D portfolios and cautiously controlling development expenditures [2] - Strong demand for laboratory testing services partially offset the revenue decline in these regions [2] Growth in China - Revenue growth in China was driven by improved capacity utilization and the company's marketing efforts [2]

Investment Rating - The report maintains a "Positive" investment rating for the pharmaceutical and biotechnology industry [4]. Core Insights - The pharmaceutical and biotechnology sector is experiencing a significant data catalyst window with the upcoming AACR annual meeting, which is expected to enhance the global competitiveness of Chinese innovative drugs [5]. - The industry index declined by 1.26%, outperforming the CSI 300 index, with notable gains in medical research outsourcing and chemical preparations [2][13]. - The overall PE ratio for the pharmaceutical and biotechnology industry is 29.30x, down from 30.34x, indicating a valuation decline below the average [17]. Industry Review - The report highlights that the medical research outsourcing and chemical preparations sectors showed positive growth, while hospitals and blood products faced declines [2][13]. - The report notes that the innovative drug licensing transactions in China exceeded $60 billion in the first quarter of 2026, indicating a strong global recognition of Chinese innovative drug assets [5]. Important Industry News - The NMPA has launched a three-year "Spring Rain Action" to promote the transformation of clinical innovation achievements in medical devices [21][26]. - Johnson & Johnson's oral IL-23R antagonist "Icotrokinra" has received FDA approval, marking it as the first of its kind globally [41]. - Novo Nordisk's weekly insulin "Awiqli" has been approved by the FDA, providing a new treatment option for type 2 diabetes patients [44]. - AstraZeneca and Amgen's TSLP monoclonal antibody "Tezepelumab" has been approved in China, becoming the first of its kind domestically [46]. Investment Suggestions - The report suggests focusing on innovative drug companies with core technology platforms and differentiated pipeline layouts, especially those expected to achieve positive catalysts at major academic conferences like AACR [5]. - It also recommends attention to the CXO/CDMO industry chain, which is expected to benefit from improved overseas R&D demand and order recovery [5].

Core Viewpoint - Tiger Med's stock rose by 2.18% on March 31, with a trading volume of 1.167 billion yuan and a market capitalization of 46.349 billion yuan [1][10]. Group 1: Company Overview - Hangzhou Tiger Med Technology Co., Ltd. specializes in providing comprehensive clinical trial services for new drug development as a Contract Research Organization (CRO) [2][11]. - The company offers a range of services including clinical operations, clinical pharmacology, regulatory affairs, scientific affairs, medical translation, pharmacovigilance, real-world research, third-party audits, data management, and statistical analysis [2][11]. - Tiger Med has established itself as a leading CRO in China, focusing on clinical research services for both domestic and international pharmaceutical and health-related products, covering phases I to IV of clinical trials [2][12]. Group 2: Strategic Partnerships and Developments - In July 2018, Tiger Med signed a strategic cooperation agreement with Jiuzhou Pharmaceutical, a leading CDMO service provider, to collaborate in the clinical research and development of innovative drugs [2][12]. - The subsidiary, Jietong Tairui, focuses on providing clinical research outsourcing services for medical devices, including registration and clinical trial services [2][12]. Group 3: Clinical Trials and Research - In 2023, the company initiated its first Phase I clinical trial for a herpes zoster protein vaccine in the U.S. and a Phase III trial for a quadrivalent meningococcal vaccine in Indonesia, enrolling over 1,400 participants [3][11]. - Tiger Med completed two large-scale Phase III efficacy studies for vaccines in collaboration with the Chinese Center for Disease Control and Prevention, with a total enrollment exceeding 38,000 participants [3][11]. Group 4: Technological Innovations - The subsidiary, Taiya Technology, developed an AI product platform for medical applications based on the open-source model Qwen2.5, providing solutions for new drug development, clinical trials, and registration [4][13]. - The AI platform has achieved excellent scores across five MedBench evaluation dimensions, including medical language understanding and generation, and is designed to enhance medical translation and knowledge inquiry [4][13]. Group 5: Financial Performance - For the year 2025, Tiger Med reported a revenue of 6.833 billion yuan, representing a year-on-year growth of 3.48%, and a net profit attributable to shareholders of 888 million yuan, up 119.15% [8][19]. - The company has distributed a total of 2.458 billion yuan in dividends since its A-share listing, with 1.154 billion yuan in the last three years [9][19].

Core Insights - The company reported a revenue of 14.095 billion yuan for the year 2025, representing a year-on-year growth of 14.82% [1] - The net profit attributable to shareholders decreased by 7.22% to 1.664 billion yuan, while the net profit excluding non-recurring items increased by 38.85% to 1.538 billion yuan [1] - The basic earnings per share were 0.9443 yuan, and the company proposed a cash dividend of 2 yuan per 10 shares (tax included) [1] Business Strategy - The company emphasizes a customer-centric service philosophy and leverages an integrated service platform to meet diverse global client needs across different research and development stages [1] - Significant achievements were noted in expanding strategic client relationships, particularly with large pharmaceutical companies [1] - The company is actively enhancing its market strategies tailored to the Chinese market, resulting in rapid growth in client business within China [1] Market Performance - The company achieved a more than 14% year-on-year increase in new order amounts for 2025 [1] - The company maintains industry leadership in small molecule fields while also experiencing rapid development in new molecular type projects [1]

Investment Rating - The report indicates a positive outlook for the biotech sector, particularly highlighting the first-time profitability of leading biotech companies, suggesting a shift towards sustainable profitability in the industry [2][3]. Core Insights - The biotech sector has shown resilience, with a weekly increase of 1.56%, outperforming the Shanghai and Shenzhen 300 index, which decreased by 1.41% [3][8]. - Leading biotech companies, such as BeiGene and Innovent Biologics, achieved their first annual profitability in 2025, marking a transition from valuation-driven to performance-driven growth in the domestic biotech market [3][12]. - The NewCo model is evolving, as evidenced by the acquisition agreement between Ouro Medicines and Gilead Sciences, which could generate significant revenue for the involved parties [3][13]. Market Weekly Review - The pharmaceutical and biotech sector saw a weekly increase of 1.56%, outperforming the Shanghai and Shenzhen 300 index, which fell by 1.41% [3][8]. - Sub-sectors such as medical research outsourcing (6.12%), raw materials (5.34%), and chemical preparations (2.88%) led the gains, while blood products (-2.95%), vaccines (-2.36%), and offline pharmacies (-1.63%) lagged [3][9]. - Notable stock performances included Meinohua (40.7%), Wanbangde (38.8%), and Fuxiang Pharmaceutical (27.6%) with significant gains, while Koyuan Pharmaceutical (-19.9%), *ST Changyao (-18.2%), and Duorui Pharmaceutical (-15.6%) faced declines [3][11]. Industry News and Key Company Announcements - Significant events include the announcement by Dize Pharmaceutical regarding promising clinical trial results for its drug in treating advanced non-small cell lung cancer [12]. - Innovent Biologics reported a revenue of 13.042 billion yuan for 2025, a 38.4% increase year-on-year, with product revenue growing by 44.6% [12][13]. - The report highlights various companies' financial performances, including a 316.29 billion yuan revenue for Heng Rui Pharmaceutical, reflecting a 13.02% year-on-year growth [13][14].

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Views - The report highlights a strong recovery in the biopharmaceutical sector, with significant growth in the "WuXi" companies, indicating a return to a prosperous cycle driven by increased demand and order expansion [4][34] - The report emphasizes the structural growth in the industry, particularly in preclinical services and small molecule CDMO, which are expected to accelerate in 2026 [5][36] Summary by Sections 1. "WuXi" Companies Performance - WuXi AppTec achieved a revenue of 45.46 billion RMB in 2025, a year-on-year increase of 15.8%, with a net profit of 19.15 billion RMB, reflecting a 102.7% increase [13] - WuXi Biologics reported a revenue of 21.79 billion RMB, up 16.7%, and a net profit increase of 45.3% [18] - WuXi STA's revenue grew by 46.7%, with a net profit increase of 69.9%, indicating strong order growth and demand recovery [26] 2. Growth Outlook for 2026 - WuXi AppTec expects a revenue growth of 18-22% for its continuing operations in 2026, with capital expenditures projected to rise to 6.5-7.5 billion RMB [4][35] - WuXi Biologics anticipates a revenue increase of 13-17% in 2026, factoring in currency fluctuations [34] - WuXi STA aims for a CAGR of 30-35% from 2025 to 2030, indicating robust growth potential [34] 3. Structural Growth Trends - The preclinical CRO sector is showing signs of recovery, with WuXi AppTec's testing services returning to positive growth and significant order increases in preclinical services [5][34] - Small molecule CDMO is expected to accelerate growth in 2026, driven by increased demand for GLP-1 class drugs [36] - ADC/XDC/TIDES CDMO sectors are maintaining high growth rates, with WuXi STA projecting a 25% CAGR over the next five years [38] 4. Market Performance - The biopharmaceutical sector rose by 1.56% in March 2026, outperforming the CSI 300 index by 2.97 percentage points [39] - The medical R&D outsourcing sector saw the largest gains, while the blood products sector experienced the most significant decline [40]

Investment Rating - The investment rating for the company is "Accumulate" [3][5] Core Insights - The company achieved strong growth in 2025, with total revenue reaching 45.456 billion yuan, a year-on-year increase of 15.84%. The revenue from continuing operations grew by 21.40% [3][4] - The net profit attributable to shareholders was 19.151 billion yuan, representing a significant year-on-year increase of 102.65%. The adjusted net profit under Non-IFRS was 14.96 billion yuan, up 41.3% year-on-year [3][4] - The company expects 2026 revenue to reach between 51.3 billion and 53 billion yuan, with a year-on-year growth of 18%-22% for continuing operations [3][4] Summary by Relevant Sections Financial Performance - In 2025, the company reported a total revenue of 45.456 billion yuan, with a 15.84% increase from the previous year. The revenue from WuXi Chemistry was 36.47 billion yuan, up 25.5%, benefiting from process optimization and capacity efficiency improvements [3][4] - The adjusted Non-IFRS gross margin for WuXi Chemistry improved by 5.9 percentage points to 52.3% [3] - The company’s overall continuing operations backlog reached 58 billion yuan, a year-on-year increase of 28.8%, indicating strong long-term visibility for performance [3] Business Segments - WuXi Chemistry: Revenue of 36.47 billion yuan, with a 25.5% increase, driven by strong performance in small molecule drug discovery and development [3] - WuXi Testing: After divesting clinical research services, revenue reached 4.04 billion yuan, a 4.7% increase, with drug safety evaluation business leading in the Asia-Pacific region [3] - WuXi Biology: Revenue of 2.68 billion yuan, a 5.2% increase, with over 20% new customer acquisition [3] Future Guidance - The company has a positive outlook for 2026, projecting revenue between 51.3 billion and 53 billion yuan, with stable adjusted Non-IFRS net profit margins [3][4] - The capital expenditure for 2026 is expected to be between 6.5 billion and 7.5 billion yuan, reflecting confidence in long-term growth [3][4]

Investment Rating - The investment rating for the company is "Buy" (maintained) for both A-shares and H-shares [7]. Core Insights - The company reported a revenue of 45.456 billion RMB for 2025, representing a year-over-year increase of 15.84%. The net profit attributable to shareholders was 19.151 billion RMB, up 102.65% year-over-year, and the adjusted non-IFRS net profit was 14.957 billion RMB, reflecting a 41.33% increase [1][5]. - The company expects a revenue growth guidance of 18-22% for 2026, supported by a strong order backlog and anticipated acceleration in growth for 2026-2027 [2][3]. - The TIDES business segment is projected to maintain high growth, with a revenue of 36.47 billion RMB in 2025, marking a 25.5% year-over-year increase, driven by a significant rise in orders and customer engagement [3][4]. Summary by Sections Financial Performance - For 2025, the company achieved a revenue of 45.456 billion RMB, with a net profit of 19.151 billion RMB, and an adjusted non-IFRS net profit of 14.957 billion RMB [1][5]. - The company anticipates revenues of 51.3-53 billion RMB for 2026, with a continued focus on maintaining a stable adjusted non-IFRS net profit margin [2]. Business Segments - WuXi Chemistry's revenue for 2025 is expected to reach 36.47 billion RMB, with a non-IFRS gross margin of 52.3%, driven by the TIDES segment's growth [3]. - The WuXi Testing and WuXi Biology segments are projected to stabilize, with revenues of 4.04 billion RMB and 2.68 billion RMB respectively for 2025, and expected growth rates of around 10% for 2026 [4]. Valuation and Estimates - The company is valued at 334.81 billion RMB for A-shares and 381.7 billion HKD for H-shares, with a target price of 112.21 RMB and 127.93 HKD respectively [5][12]. - The earnings per share (EPS) estimates for 2026, 2027, and 2028 are projected to be 5.66 RMB, 6.72 RMB, and 7.88 RMB respectively, reflecting an upward adjustment due to better-than-expected growth in the TIDES segment [5][11].